Welcome to our dedicated page for Coherus news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus stock.
Coherus Oncology (CHRS) generates news typical of a commercial-stage oncology company, spanning clinical trial results, regulatory developments, and corporate strategy updates. As a company that transformed from biosimilars to dedicated cancer therapeutics, news coverage reflects both its commercial product performance and pipeline advancement.
Clinical development news centers on LOQTORZI, the company's approved anti-PD-1 checkpoint inhibitor for nasopharyngeal carcinoma, including follow-up survival data and potential label expansions. Pipeline updates feature CHS-114, the company's anti-CCR8 antibody program, with news from conferences like SITC and AACR presenting biomarker data and early clinical results.
Corporate news covers quarterly financial results, strategic partnerships, and clinical collaborations with other pharmaceutical companies. The company's transformation from biosimilars to oncology has generated significant news around divestitures, debt management, and organizational changes.
Investors tracking CHRS benefit from monitoring FDA regulatory announcements, clinical trial milestones, and partnership developments that can materially impact the company's commercial trajectory. Conference presentations at major oncology meetings often provide the first look at clinical data before publication.
Coherus Oncology (NASDAQ: CHRS) said senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30 a.m. PT.
The presentation and Q&A will stream via webcast and a link will be posted on the company's Investor Events Calendar at https://investors.coherus.com/events-presentations. The webcast replay will be available through February 13, 2026.
Coherus Oncology (NASDAQ: CHRS) announced publication in Molecular Cancer Therapeutics describing preclinical and first-in-human biomarker data for investigational anti-CCR8 antibody tagmokitug (CHS-114).
Key findings: picomolar binding affinity, no off-target binding, selective depletion of CCR8+ regulatory T cells, high prevalence and density of CCR8 across many solid tumors, tumor regression in mouse models with enhanced activity when combined with anti-PD-1, and translational proof-of-mechanism showing selective CCR8+ Treg reductions in patients.
The publication supports ongoing clinical development of tagmokitug in combination with toripalimab across multiple solid tumor settings.
Coherus (NASDAQ: CHRS) reported six-year follow-up from the Phase 3 JUPITER-02 trial showing LOQTORZI (toripalimab-tpzi) plus gemcitabine and cisplatin achieved a median overall survival of 64.8 months vs 33.7 months for chemotherapy alone (31-month improvement; HR 0.62; 95% CI 0.45–0.85).
Results presented at ESMO Asia 2025 reinforce LOQTORZI plus chemotherapy as a first-line option for recurrent or metastatic nasopharyngeal carcinoma and summarize key safety findings including immune-mediated adverse events.
Coherus Oncology (NASDAQ: CHRS) reported multiomic biomarker data for CHS-114 from the Phase 1b dose expansion and safety arms in recurrent/metastatic HNSCC on Nov 7, 2025.
Key findings: CHS-114 selectively depleted intratumoral CCR8+ Tregs by 74% and reduced total FOXP3+ Tregs by 43%, while increasing intratumoral CD8+ T cells by 73% and raising the CD8+/CCR8+ Treg ratio 12-fold. Peripheral blood showed sustained CD8+ activation and proliferation with combination dosing. Safety was described as manageable; a partial response was observed in one refractory HNSCC patient. Data were presented at SITC 2025 (abstract #640) with the presentation on Nov 8, 2025.
Coherus Oncology (NASDAQ: CHRS) reported Q3 2025 results and a business update on Nov 6, 2025. LOQTORZI net revenue was $11.2M in Q3, up 12% QoQ and 92% YoY; total net revenue from continuing operations was $11.6M for the quarter. Cash, cash equivalents and marketable securities were $191.7M as of Sept 30, 2025. R&D spending rose to $27.3M in Q3 while SG&A declined to $24.9M. Net loss from continuing operations was $44.5M, or $(0.38) per share, with non-GAAP net loss of $38.9M. Pipeline progress includes expansion of CHS-114 into colorectal cancer and multiple 2026 readouts for CHS-114 and casdozokitug.
Coherus Oncology (Nasdaq: CHRS) announced on Nov 6, 2025 that Arvind Sood has joined as Chief Strategy and Corporate Affairs Officer, reporting to Denny Lanfear, Chairman and CEO. His remit includes corporate development, investor relations and government affairs. Management said Sood will help clarify Coherus Oncology's value proposition to investors and partners as the company advances commercialization of LOQTORZI® in nasopharyngeal carcinoma and develops pipeline programs: CCR8-targeting antibody CHS-114 (head & neck, gastric, esophageal, colorectal) and IL-27 antagonist casdozokitug (liver, lung). Sood brings over 20 years of senior biopharma experience including roles at Amgen, Innate Pharma, Curogen and Aventis/Sanofi, and holds an MBA and BBA.
Coherus Oncology (Nasdaq: CHRS) will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. The company will host a conference call and webcast starting at 5:00 p.m. Eastern Time on November 6, 2025 to discuss results and provide a business update.
Investors must pre-register for dial-in details and a PIN; a live webcast and an archived replay will be available on the company’s Investors website at https://investors.coherus.com. The press release and related materials will be posted on the same site before the call begins.
Coherus Oncology (NASDAQ: CHRS) will webcast presentations at three investor conferences in Nov–Dec 2025: the UBS Global Healthcare Conference in Palm Beach Gardens on Nov 10, 2025 at 1:15 PM ET, the Jefferies Global Healthcare Conference in London on Nov 18, 2025 at 10:30 AM GMT, and the Baird Biotech Discovery Series virtual event on Dec 17, 2025 at 1:30 PM ET.
Webcasts and 30-day replays will be available on the company’s Investor Events page at https://investors.coherus.com/events-presentations. One-on-one meeting requests should be coordinated through your bank representative. The company uses its investor website to disclose material non-public information and comply with Regulation FD.
Coherus Oncology (NASDAQ: CHRS) will present a poster at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), Nov 5-9, 2025, in National Harbor, Maryland. Abstract #640 reports that CHS-114, an anti-CCR8 cytolytic monoclonal antibody, “demonstrates selective intratumoral Treg depletion and favorable immune remodeling” in participants with advanced solid tumors. The poster presentation is scheduled for Saturday, November 8, 2025 at Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
Additionally, CHS-114 will be featured in SITC’s webinar series "Targets for Cancer IO: A Deep Dive" on October 22, 2025, 12:00–2:00 PM ET, covering CCR8 biology and clinical results, with Coherus faculty Rosh Dias, MD and Varun Kapoor, PhD.
Coherus Oncology (NASDAQ:CHRS) announced its participation in three upcoming investor conferences in September and October 2025. The company will present at the Baird 2025 Global Healthcare Conference on September 9, the H.C. Wainwright Global Investment Conference on September 10, and the UBS Virtual Oncology Day on October 1, 2025.
All presentations will be accessible through webcast links on the company's investor relations website, with replays available for 30 days. Investors interested in one-on-one meetings with management should contact their respective bank representatives.
FAQ
What is the current stock price of Coherus (CHRS)?
What is the market cap of Coherus (CHRS)?
